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1. Introduction
The number of life-threatening infectious diseases caused by
multidrug-resistant bacteria has reached an alarming level in
many countries around the world. Recently, the Severe Acute
Respiratory Syndrome (SARS) caused by the novel coronavi-
rus SARS-CoV (Chang et al., 2007; Yeung and Meanwell,
2007) and bird ﬂu caused by avian inﬂuenza (H5N1) virus
(Gary and Ting, 2007) have emerged as two important infec-
tious diseases with pandemic potential. Both infections crossed
ET
y. Production and hosting by
Saud University.
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ND license.the species barrier to infect humans. Also, the ever growing
demand for material protection from microbial contamination
is a serious challenge (Berber et al., 2003). The aforementioned
facts are a cause of great concern and create a pressing need
for new antibacterial agents.
Despite great effort from the pharmaceutical industry to
manage the resistance problem, the discovery and development
of new mechanistic classes of antibiotics has found with very
little success (Taun et al., 2007). The difﬁculty of this task is
demonstrated by the fact that only two antibiotics of new clas-
ses, linezolid (an oxazolidinone) and daptomycin (a cyclic lip-
opeptide), have been successfully developed in the past three
decades (Carpenter and Champers, 2004; Grunder et al.,
2006; Weigelt et al., 2005).
Quinazoline derivatives represent one of the most active
classes of compounds possessing a wide spectrum of biological
activity (Apfel et al., 2001). They are widely used in pharmaceu-
ticals and agrochemicals (Tobe et al., 2003); for example, ﬂuqu-
inconazole fungicide for the control of agriculture diseases
(Guang-Fang et al., 2007). Several reports have been published
on the biological activity of quinazoline derivatives, including
their bactiricidal, herbal and anti-tumor activity (Jiang et al.,
96 A.A. Kadi1990; Gursoy and Ilhan, 1995; Raffa et al., 1999; Chenard et al.,
2001). Thus, their synthesis has been of great interest in the
elaboration of biologically active heterocyclic compounds.
Recently, it was reported that some iodoquinazolines exhib-
ited moderate antibacterial activity (Alafeefy, 2008). Prompted
by these ﬁndings, this article reports the design and synthesis
of an extension series of 3-substituted 2-phenylquinazolin-
4(3H)-one derivatives and tested their antibacterial activities.A2. Materials and methods
2.1. Chemistry
All melting points (C, uncorrected) were determined in open
capillaries on a Gallenkamp melting point apparatus (Sanyo
Gallenkamp, Southborough, UK). IR spectra (KBr, v max:
cm1) were recorded on a Perkin-Elmer spectrophotometer
(577 model; Perkin-Elmer, Rotkreuz, Switzerland). NMR
spectra were recorded on Bruker AC-300 Ultra Shield NMR
spectrometer (Bruker, Flawil, Switzerland; dppm) at
300 MHz for 1H and 75 MHz for 13C, using TMS as internal
standard, and peak multiplicities are designated as follows: s,
singlet; d, doublet; t, triplet; q, quartet; br s, broad singlet;
m, multiplet. Mass spectra were recorded on a Jeol D-300
(EI/CI) spectrometer (Jeol, Tokyo, Japan). Elemental analyses
were performed on a Carlo Erba 1108 Elemental Analyzer
(Heraeus, Hanau, Germany) and were less than 0.4% of theo-
retical values.
2.1.1. Methyl [2-phenyl-4-oxo-quinazolin-3(4H)-yl]-
dithiocarbamate (3)
To a vigorously stirred solution of 3-amino-2-phenylquinazo-
lin-4(3H)-one (1, 4.74 g, 0.02 mol) in dimethylsulfoxide
(10 mL) at room temperature, carbondisulﬁde (1.9 g,
0.026 mol) and aqueous sodium hydroxide (1.2 mL,
0.02 mol) were added dropwise. After 30 min, dimethylsulfate
(3.15 g, 0.025 mol) was added dropwise while cooling in an ice
bath. Stirring was continued for 3 h, and then the reaction
mixture was poured into an ice–water mixture. The precipi-
tated solid was ﬁltered, dried, and crystallized from acetic acid.
3: IR (KBr, cm1) 3308 (NH), 2916, 2857 (CH aliph.), 1680
(C‚O). 1H NMR: 2.30 (s, 3H, CH3), 7.27–8.23 (m, 9H, Ar-
H), 9.02 (br s, 1H, NH, D2O exchang.).
13C NMR: 22
(CH3), 120, 125, 127, 129, 131, 133, 139, 145, 153, 155 (Ar-
C), 167 (C‚O), 199 (C‚S). MS, m/z (Rel. Int.): 326 (M+,
23), 292 (25), 270 (43), 235 (11), 222 (100).ET
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2.1.2. 1-[2-Phenyl-4-oxo-quinazolin-3(4H)-yl]-3-substituted
thiourea derivatives (4–8)
A mixture of 2 (3.52 g, 0.01 mol) and the appropriate isothio-
cyanate (0.01 mol) in absolute ethanol (30 mL) was heated un-
der reﬂux for 2 h. The reaction mixture was cooled, and the
solid separated was ﬁltered, dried, and crystallized from acetic
acid.
4: IR (KBr, cm1) 3308, 3200 (2NH), 3052 (CH arom.),
2916, 2857 (CH aliph.), 1710, 1680 (2C‚O). 1H NMR: 2.73
(s, 3H, CH3), 7.25–8.12 (m, 9H, Ar–H), 8.40 (br s, 1H, NH,
D2O exchang.), 9.32 (br s, 1H, NH, D2O exchang.).
13C
NMR: 35 (CH3), 120, 125, 127, 129, 131, 133, 139, 145, 153,
155, (Ar-C), 167 (C‚O), 199 (C‚S). MS, m/z (Rel. Int.):
310 (M+, 35), 77 (100). 5: IR (KBr, cm1) 3309, 3210
R(2NH), 3060 (CH arom.), 2912, 2864 (CH aliph.), 1701, 1682
(2C‚O). 1H NMR: 1.05 (t, 3H, CH3), 2.50 (m, 2H, CH2),
7.25–8.12 (m, 9H, Ar-H), 8.41 (br s, 1H, NH, D2O exchang.),
9.30 (br s, 1H, NH, D2O exchang.).
13C NMR: 15 (CH3), 34
(CH2), 119, 124, 127, 130, 131, 134, 138, 146, 152, 154, (Ar-
C), 167 (C‚O), 199 (C‚S). MS, m/z (Rel. Int.): 323 (M+,
35), 77 (100). 6: IR (KBr, cm1) 3295, 3203 (2NH), 3053
(CH arom.), 2911, 2856 (CH aliph.), 1712, 1681 (2C‚O). 1H
NMR: 4.27 (d, 2H, CH2), 5.25 (m, 1H, ‚CH), 5.33 (d, 2H,
CH2), 7.29–8.30 (m, 9H, Ar-H), 8.42 (br s, 1H, NH, D2O ex-
chang.), 9.35 (br s, 1H, NH, D2O exchang.).
13C NMR: 51
(CH2), 118, 119, 125, 127, 129, 131, 133, 137, 139, 145, 153,
164 (Ar-C, allyl-C), 167 (C‚O), 189 (C‚S). MS, m/z (Rel.
Int.): 336 (M+, 21), 245 (75), 116 (100). 7: IR (KBr, cm1)
3304, 3201 (2NH), 3057 (CH arom.), 2914, 2856 (CH aliph.),
1710, 1687 (2C‚O). 1H NMR: 4.73 (s, 2H, CH2), 7.26–8.31
(m, 14H, Ar-H), 8.61 (br s, 1H, NH, D2O exchang.), 9.49
(br s, 1H, NH, D2O exchang.).
13C NMR: 53 (CH2), 119,
125, 127, 129, 130, 131, 133, 139, 145, 153, 155 (Ar-C), 166
(C‚O), 190 (C‚S). MS, m/z (Rel. Int.): 386 (M+, 19), 224
(75), 161 (24), 91 (100). 8: IR (KBr, cm1) 3304, 3201
(2NH), 3057 (CH arom.), 1710, 1687 (2C‚O). 1H NMR:
7.01–8.13(m, 14H, Ar-H), 8.76 (br s, 1H, NH, D2O exchang.),
9.45 (br s, 1H, NH, D2O exchang.).
13C NMR: 120, 125, 127,
129, 132, 133, 139, 140, 145, 153, 164 (Ar-C), 167 (C‚O), 188
(C‚S). MS, m/z (Rel. Int.): 372 (M+, 25), 224 (75), 147 (21),
77 (100).
2.1.3. Phenacyl-[2-phenyl-4-oxo-quinazolin-3(4H)-yl]-
dithiocarbamate derivatives (9–13)
A mixture of 2 (3.52 g, 0.01 mol), anhydrous potassium car-
bonate (1.38 g, 0.01 mol) and the appropriate phenacyl halide
(0.01 mol) in isopropanol (30 mL) was reﬂuxed for 3 h. The
solvent was removed under reduced pressure and the separated
solid was ﬁltered, dried, washed with water and crystallized
from acetic acid.
9: IR (KBr, cm1) 3287 (2NH), 3072 (CH arom.), 2985 (CH
aliph.), 1700, 1683 (2C‚O), 1213 (C‚S). 1H NMR: 4.50 (s,
2H, CH2CO), 7.25–8.31 (m, 14H, Ar-H), 8.65 (br s, 1H, NH,
D2O exchang.).
13C NMR: 46 (CH2), 120, 125, 127, 128,
129, 131, 134, 137, 145, 152, 154, 156 (Ar-C), 168, 179
(2C‚O), 190 (C‚S). MS, m/z (Rel. Int.): 431 (M+, 25), 235
(39), 159 (14), 120 (100). 10: IR (KBr, cm1) 3285 (NH),
3065 (CH arom.), 2983 (CH aliph.), 1705, 1679 (2C‚O),
1225 (C‚S). 1H NMR: 4.45 (s, 2H, CH2CO), 7.20–8.30 (m,
13H, Ar-H), 8.70 (br s, 1H, NH, D2O exchang.).
13C NMR:
46 (CH2), 119, 125, 127, 128, 129, 130, 131, 135, 137, 138,
147, 153, 163 (Ar-C), 167, 180 (2C‚O), 191 (C‚S). MS,
m/z (Rel. Int.): 510 (M+ +2, 13), 508 (M+, 14), 184 (100).
11: IR (KBr, cm1) 3277 (NH), 3069 (CH arom.), 2974 (CH
aliph.), 1703, 1676 (2C‚O), 1221 (C‚S). 1H NMR: 4.55 (s,
2H, CH2CO), 7.30–8.31 (m, 13H, Ar-H), 8.60 (br s, 1H, NH,
D2O exchang.).
13C NMR: 46 (CH2), 119, 125, 126, 127,
129, 131, 135, 138, 140, 145, 152, 163 (Ar-C), 169, 179
(2C‚O), 192 (C‚S). MS, m/z (Rel. Int.): 465 (M+ +2, 3),
463 (M+, 8), 140 (100). 12: IR (KBr, cm1) 3259 (NH), 3051
(CH arom.), 2967 (CH aliph.), 1698, 1687 (2C‚O), 1219
(C‚S). 1H NMR: 4.60 (s, 2H, CH2CO), 7.35–8.40 (m, 13H,
Ar-H), 8.70 (br s, 1H, NH, D2O exchang.).
13C NMR: 44
(CH2), 122, 124, 125, 127, 128, 130, 132, 135, 137, 138, 149,
155, 161 (Ar-C), 166, 178 (2C‚O), 191 (C‚S). 13: IR (KBr,
cm1) 3282 (NH), 3061 (CH arom.), 2968 (CH aliph.), 1703,
CT
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A1672 (2C‚O), 1214 (C‚S). 1H NMR: 2.55 (s, 3H, CH3), 4.65
(s, 2H, CH2CO), 7.20–8.15 (m, 13H, Ar-H), 8.45 (br s, 1H,
NH, D2O exchang.).
13C NMR: 29 (CH3), 45 (CH2), 119,
120, 124, 127, 128, 130, 132, 135, 137, 138, 147, 154, 162
(Ar-C), 168, 180 (2C‚O), 194 (C‚S). MS, m/z (Rel. Int.):
445 (M+, 17), 362 (33), 119 (100).
2.1.4. 2-Phenyl-3-[4-substituted-2-thioxothiazol-3(2H)-yl]-
quinazolin-4(3H)-one derivatives (14–18)
A mixture of the appropriate dithiocarbamate derivative 9–13
(0.01 mol), and sodium ethoxide (0.68 g, 0.01 mol) in absolute
ethanol (30 mL) was heated under reﬂux for 3 h. The solvent
was removed under reduced pressure, and the obtained solid
was washed with water and crystallized from acetic acid.
14: IR (KBr, cm1) 3065 (CH arom.), 1688 (C‚O), 1220
(C‚S). 1H NMR: 7.15–8.31 (m, 15H, Ar-H). 13C NMR:
119, 111, 125, 127, 128, 129, 130, 131, 135, 138, 145, 153,
160, 164 (Ar-C), 167 (C‚O), 188 (C‚S). MS, m/z (Rel.
Int.): 413 (M+, 26), 193 (100). 15: IR (KBr, cm1) 3062 (CH
arom.), 1685 (C‚O), 1224 (C‚S). 1H NMR: 6.95–8.31 (m,
14H, Ar-H). 13C NMR: 119, 111, 125, 127, 129, 130, 131,
133, 135, 136, 139, 145, 153, 160, 164, 167, 188 (Ar-C, C‚O
and C‚S). 16: IR (KBr, cm1) 3086 (CH arom.), 1698
(C‚O), 1231 (C‚S). 1H NMR: 6.95–8.31 (m, 14H, Ar-H).
13C NMR: 119, 111, 125, 127, 129, 130, 131, 133, 135, 136,
139, 145, 153, 160, 164 (Ar-C), 169 (C‚O), 186 (C‚S). 17:
IR (KBr, cm1) 3073 (CH arom.), 1681 (C‚O), 1212
(C‚S). 1H NMR: 7.0–8.24 (m, 14H, Ar-H). 13C NMR: 119,
111, 124, 125, 127, 129, 130, 131, 133, 139, 43, 145, 150, 153,
160, 164 (Ar-C), 168 (C‚O), 188 (C‚S). 18: IR (KBr, cm
1) 3055 (CH arom.), 1680 (C‚O), 1222 (C‚S). 1H NMR:
2.75 (s, 3H, CH3), 6.95–8.28 (m, 14H, Ar-H).
13C NMR: 27
(CH3), 119, 111, 125, 127, 129, 131, 132, 133, 134, 139, 140,
145, 153, 160, 163 (Ar-C), 166 (C‚O), 188 (C‚S).
2.1.5. 4-[2-Phenyl-4-oxo-quinazolin-3(4H)-
yl]thiosemicarbazide (19)
Solution of 3 (3.26 g, 0.01 mol) in ethanol was treated with
hydrazine hydrate (98%; 4.9 g, 0.1 mol) and heated on water
bath until methyl mercaptan evolution ceased. After cooling,
the solid obtained was ﬁltered, dried, and crystallized from
acetic acid.
19: IR (KBr, cm1) 3315, 3272, 3196 (NH, NHNH2), 3062
(CH arom.), 1678 (C‚O), 1217 (C‚S). 1H NMR: 4.17 (br s,
2H, NH2, D2O exchang.), 6.75 (br s, 1H, NH, D2O exchang.),
7.22–8.15 (m, 9H, Ar-H), 8.65 (br s, 1H, NH, D2O exchang.).
13C NMR: 119, 125, 127, 129, 131, 133, 139, 145, 153, 164 (Ar-
C), 167 (C‚O), 188 (C‚S). MS, m/z (Rel. Int.): 311 (M+, 6),
292 (31), 221 (16), 77 (100).
2.1.6. 1-Acyl-4-[2-phenyl-4-oxo-quinazolin-3(4H)-
yl]thiosemicarbazide derivatives (20–24)
The appropriate acid chloride (0.001 mol), was added slowly to
a solution of 19 (0.31 g, 0.001 mol) in pyridine (10 mL) and the
reaction mixture was stirred at room temperature for 1 h. The
solvent was removed and the residue was treated with dilute
hydrochloric acid, washed with water, ﬁltered, and crystallized
from acetic acid to afford the target compounds in good yields.
20: IR (KBr, cm1) 3297, 3274, 3168 (NH, NHNH), 3079
(CH arom.), 1680, 1653 (2C‚O), 1214 (C‚S). 1H NMR:
2.67 (s, 3H, CH3), 7.20–8.15 (m, 9H, Ar-H), 8.44 (br s, 1H,
NH, D2O exchang.), 9.25 (br s, 1H, NH, D2O exchang.),
RE
TR10.13 (br s, 1H, NH, D2Oexchang.).
13C NMR: 28 (CH3),
119, 125, 127, 129, 131, 133, 139, 145, 153, 164 (Ar-C), 167,
171 (2C‚O), 189 (C‚S). MS, m/z (Rel. Int.): 353 (M+, 2),
334 (7), 318 (10), 279 (19), 73 (100). 21: IR (KBr, cm1)
3285, 3271, 3168 (NH, NHNH), 3072 (CH arom.), 2937 (CH
aliph.), 1688, 1654 (2C‚O), 1230 (C‚S). 1H NMR: 1.94 (t,
3H, CH3), 2.55 (q, 2H, CH2), 7.26–8.15 (m, 9H, Ar-H), 8.46
(br s, 1H, NH, D2O exchang.), 9.33 (br s, 1H, NH, D2O ex-
chang.), 10.28 (br s, 1H, NH, D2O exchang.).
13C NMR: 16
(CH3), 36 (CH2), 119, 125, 127, 129, 131, 133, 139, 145, 153,
164 (Ar-C), 166, 173 (2C‚O), 189 (C‚S). MS, m/z (Rel.
Int.): 367 (M+, 2), 298 (7), 87 (100). 22: IR (KBr, cm1)
3265, 3243, 3162 (NH, NHNH), 3068 (CH arom.), 2956 (CH
aliph.), 1681, 1659 (2C‚O), 1228 (C‚S). 1H NMR: 3.68 (s,
2H, CH2), 7.14-8.26 (m, 14H, Ar-H), 8.56 (br s, 1H, NH,
D2O exchang.), 9.23 (br s, 1H, NH, D2O exchang.), 10.15
(br s, 1H, NH, D2O exchang.).
13C NMR: 46 (CH2), 119,
125, 127, 129, 131, 132, 133, 139, 140, 145, 153, 164 (Ar-C),
168, 172 (2C‚O), 189 (C‚S). MS, m/z (Rel. Int.): 429
(M+, 2), 410 (9), 91 (100). 23: IR (KBr, cm1) 3264, 3249,
3165 (NH, NHNH), 3065 (CH arom.), 1687, 1654 (2C‚O),
1226 (C‚S). 1H NMR: 7.26–8.31 (m, 14H, Ar-H), 8.66 (br
s, 1H, NH, D2O exchang.), 9.23 (br s, 1H, NH, D2O exchang.),
10.15 (br s, 1H, NH, D2O exchang.).
13C NMR: 119, 125, 127,
129, 130, 132, 133, 135, 137, 139, 145, 153, 164 (Ar-C), 167, 172
(2C‚O), 189 (C‚S). MS, m/z (Rel. Int.): 415 (M+, 2), 396
(9), 348 (20), 135 (100). 24: IR (KBr, cm1) 3260, 3234, 3158
(NH, NHNH), 3062 (CH arom.), 2963 (CH aliph.), 1690,
1657 (2C‚O), 1225 (C‚S). 1H NMR: 2.82 (s, 3H, CH3),
7.25–8.33 (m, 12 H, Ar-H), 8.58 (br s, 1H, NH, D2O exchang.),
9.30 (br s, 1H, NH, D2O exchang.), 10.02 (br s, 1H, NH, D2O
exchang.). 13C NMR: 28 (CH3), 119, 125, 127, 129, 131, 132,
133, 135, 139, 145, 153, 164 (Ar-C), 166, 171 (2C‚O), 191
(C‚S). MS, m/z (Rel. Int.): 429 (M+, 1.6), 348 (23), 77 (100).
2.2. Determination of the in vitro antimicrobial activity
All the synthesized compounds were tested for their in vitro
antimicrobial activity against a panel of standard strains of
the Gram-positive bacteria, Staphylococcus aureus ATCC
19433 (SA) and Bacillus subtilis ATCC 6633 (BS), the Gram-
negative bacteria, Escherichia coli ATCC 25922 (EC) and
Pseudomonas aeruginosa ATCC 27853 (PA), and the yeast-like
pathogenic fungus Candida albicans ATCC 753 (CA). The pri-
mary screening was carried out using the agar-disk diffusion
method using Muller-Hinton agar medium (Patrick et al.,
1995). Sterile ﬁlter paper disks (8 mm diameter) were moist-
ened with the test compound solution in dimethylsulfoxide
of speciﬁc concentration (200 lg/disk). The disks containing
the compounds under test, the antimicrobial antibiotic ampi-
cillin trihydrate (100 lg/disk) and antifungal drug clotrimazole
(100 lg/disk), were carefully placed on the agar culture plates
that had been previously inoculated separately with the
microorganisms suspension at 106 Colony Forming Unit/mL
(CFU/mL) concentration. The plates were incubated at
37 C, and the diameter of the growth inhibition zones was
measured after 24 h in case of bacteria and 48 h in case of C.
albicans. The minimal inhibitory concentration (MIC) for the
most active compounds against the same microorganisms used
in the primary screening was carried out using the microdilu-
tion susceptibility method in Muller-Hinton broth and Sabou-
raud liquid medium. The compounds, ampicillin trihydrate,
TE
D
98 A.A. Kadiand clotrimazole were dissolved in dimethylsufoxide at con-
centration 800 lg/mL. The twofold dilutions of the solution
were prepared (400, 200, 100, . . . 6.25 lg/mL). The microor-
ganism suspensions at 106 CFU/mL concentrations were inoc-
ulated to the corresponding wells. The plates were incubated at
37 C for 24 and 48 h for the bacteria and C. albicans, respec-
tively. The MIC values were determined as the lowest concen-
tration that completely inhibited visible growth of the
microorganisms as detected by unaided eye.
3. Results and discussion
3.1. Chemistry
The synthetic route designed for the synthesis of the target
compounds is summarized in Scheme 1. The key intermediates
3-amino-2-phenylquinazolin-4(3H)-one 1 and the potassium
dithiocarbamate derivative 2 were prepared according to a re-
ported procedure (Alafeefy, 2008). The 3-amino function of 1
was utilized to produce the 3-thioureido analogs 4–8 via its
reaction, in absolute ethanol, with some selected isothiocya-N
N
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Anates where two NH absorption bands appeared in the IR
spectra around 3300, 3200 cm1, in addition to the carbonyl
band at around 1680 cm1. The dithiocarbamate derivative 3
was obtained by adopting a reported procedure (Prasad
et al., 2000). The potassium salt was converted to the dithioic
acid esters 9–13 through reaction with the appropriate a-halo-
actophenone; generally, the IR spectra of these compounds re-
vealed the presence of two carbonyl bands around 1710,
1680 cm1 and an NH band around 3260 cm1. Cyclization
of these esters was accomplished using sodium ethoxide to
yield the corresponding 3-[4-substituted-2 thioxothiazol-
3(2H)-yl]-quinazolin-4(3H)-one derivatives 14–18. The IR
spectra of these cyclic derivatives revealed the absence of the
carbonyl band as well as the absence of the NH band. Hydra-
zinolysis of the intermediate 3 afforded the corresponding thi-
osemicarbazide derivative 19. The IR spectra of compound 19
revealed the absence of the aliphatic absorption band. The N-
acyl derivatives 20–24 were obtained through reacting 19 with
some selected acid chlorides (Scheme 1; Table 1); the IR spec-
tra of the products exhibited two strong carbonyl bands
around 1700 and 1670 cm1. The structures of all the newly
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Table 1 Physical data of compounds 3–24.
Cpd. No. R M.P. (C) Yield (%) Mol. Formula (mol. wt.)
3 –– 212–14 77 C16H13N3OS2 (327.42)
4 CH3 156–58 75 C16H14N4OS (310.37)
5 C2H5 230–32 81 C17H16N4OS (324.40)
6 CH2CH‚CH2 169–71 80 C18H16N4OS (336.41)
7 CH2C6H5 190–92 82 C22H18N4OS (386.47)
8 C6H5 163–65 85 C21H16N4OS (372.44)
9 H 126–28 90 C23H17N3O2S2 (431.53)
10 Br 195–97 91 C23H16BrN3O2S2 (510.43)
11 Cl 180–82 91 C23H16ClN3O2S2 (465.98)
12 NO2 202–04 91 C23H16N4O4S2 (476.53)
13 CH3 121–23 85 C24H19N3O2S2 (445.56)
14 H 174–76 84 C23H15N3OS2 (413.51)
15 Br 160–62 80 C23H14BrN3OS2 (492.41)
16 Cl 111–13 82 C23H14ClN3OS2 (447.96)
17 NO2 157–59 80 C23H14N4O3S2 (458.51)
18 CH3 200–02 75 C24H17N3OS2 (427.54)
19 –– 146–48 71 C15H13N5OS (311.36)
20 CH3 184–86 71 C17H15N5O2S (353.40)
21 C2H5 155–57 73 C18H17N5O2S (367.42)
22 CH2C6H5 149–51 75 C23H19N5O2S (429.49)
23 C6H5 167–69 78 C22H17N5O2S (415.47)
24 C6H4(CH3)-p 134–36 65 C23H19N5O2S (429.49)
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A
EDsynthesized compounds were further conﬁrmed by elemental
analyses in addition to the IR, 1H NMR, 13C NMR, and mass
spectral data, which were in full agreement with their proposed
structures.
3.2. Antimicrobial activity
The results of the preliminary antimicrobial testing of com-
pounds 1–24 (200 lg/disk) and the broad-spectrum antibacte-
rial antibiotic ampicillin trihydrate (100 lg/disk) are shown
in Table 2. The results revealed that, except compounds 9–
18, the majority of the synthesized compounds showed varying
degrees of inhibition against the tested microorganisms. In
general, the inhibitory activity against the tested Gram-posi-
tive bacteria was higher than that of the Gram-negative one,
in addition, these derivatives showed weak activity against
P. aeruginosa and C. albicans. Compounds 4–6, 19–22 andTR
Table 2 Antimicrobial activity of compounds (200 lg/8 mm disk
(100 lg/8 mm disk) and the antifungal drug Clotrimazole (100 lg/8 m
6633 (BS), E. coli ATCC 25922 (EC), P. aeruginosa ATCC 27853 (P
Cpd. No. MIC (lg/mL)
SA BS
4 12.5 12.5
5 25 25
6 50 50
19 50 100
20 50 50
21 12.5 12.5
22 50 50
24 50 50
Ampicillin <6.25 <6.25
Clotrimazole NT NT
NT, not tested.
R24 displayed broad-spectrum antimicrobial activity; they pos-
sessed excellent activity against the Gram-positive bacteria,
moderate activity against E. coli, and weak activity against
C. albicans. The least susceptible organisms were P. aeruginosa
and C. albicans. Only compound 4, was moderately active
against C. albicans and compounds 20 and 24 showed moder-
ate activity against E. coli. However, compound 21 exhibited
moderate activity against E. coli and P. aeruginosa in addition
to weak activity against C. albicans. The other compounds
were either weakly active or completely inactive against the
tested strains. None of the tested compounds were found to
be as strong as clotrimazole. However, the dithiocarbamate
derivatives 9–13 and the corresponding cyclic, dehydrated,
derivatives 14–18 were almost inactive. The structural–antimi-
crobial activity relationship of the synthesized compounds,
based on the structure of the starting compound 1, which
possessed very weak antimicrobial activity, revealed that the
T), the broad-spectrum antibacterial drug ampicillin trihydrate
m disk) against S. aureus ATCC 19433 (SA), B. subtilis ATCC
A), and C. albicans ATCC 753 (CA).
EC PA CA
50 100 50
100 100 100
100 100 100
100 100 100
50 100 100
50 50 100
100 100 100
50 100 100
<6.25 <6.25 NT
NT NT 12.5
100 A.A. Kadiintroduction of thioureides enhances the antimicrobial activity
according to the nature of the substituent group. The alkyl
thioureides had greater inﬂuence on the activity than the aryl
substituent. The methyl and ethyl derivatives 4, 5 were found
to be more active than the allyl derivative 6 and the aryl deriv-
atives 7 and 8. The maximum activity, within this series, was
attained with compound 4 (R CH3). Meanwhile, the majority
of the carbohydrazide derivatives 19–24 showed good activity
although the precursor compound 3 was found to be totally
inactive. Also, it was clear that the aliphatic carbohydrazide
derivatives 19–21 were more active than the aromatic deriva-
tives 22–24. The most active derivatives in this series were com-
pounds 20 (R CH3) and 21 (R C2H5).AAcknowledgements
The author expresses his sincere thanks and gratitude to Dr.
Hasan A. Samaha, Department of Microbiology, College of
Pharmacy, Al-Azhar University, Cairo, Egypt, for carrying
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